Results 301 to 310 of about 203,970 (332)

Interferon alpha in the therapy of CML

British Journal of Haematology, 1991
This paper summarizes the experience with interferon alpha (IFNα) as single‐agent therapy and in combination gathered at M. D. Anderson Cancer Center. It also covers some of the laboratory research associated with these clinical studies.
Moshe Talpaz, Razelle Kurzrock, Hagop M. Kantarjian, J. U. Gutterman   +3 more
openaire   +3 more sources

Protein Engineering of Interferon Alphas

2005
Interferon (IFN)-alphas constitute a family of proteins exhibiting high degree of homology in primary, secondary, and tertiary structure and display a high level of species specificity in their biological properties. However, small structural differences in these proteins may be responsible for a significant variety of biological actions. Understanding
Renqiu Hu, Ke-jian Lei, Kathryn C. Zoon, Joseph Bekisz   +3 more
openaire   +2 more sources

Interferon-alpha for maintenance of follicular lymphoma

Cochrane Database of Systematic Reviews, 2010
Indolent non-Hodgkin's lymphoma, in particular follicular lymphoma (FL), is characterized by multiple remissions and relapses. Several studies have used interferon-alpha (IFN) to control this disease, both as induction and as maintenance therapy.
Baldo P, Rupolo M, Compagnoni A, Lazzarini R, Bearz A, Cannizzaro R, Spazzapan S, Truccolo I, Moja L   +8 more
openaire   +4 more sources

MANAGEMENT OF PLEXIFORM NEUROFIBROMA WITH INTERFERON ALPHA

Pediatric Hematology and Oncology, 2008
Plexiform neurofibroma is a relatively common but potentially devastating manifestation of neurofibromatosis type 1 (NF 1). A substantial number of plexiform neurofibroma causes morbidity. Various treatment modalities are considered to decrease pain. In this paper a case with plexiform neurofibroma causing severe pain and in whom alpha-interferon was ...
Citak, Elvan Caglar, Memis, Leyla, Boyunaga, ÖZNUR LEMAN, KARADENİZ, CEYDA, OKUR, ARZU, Oguz, Aynur   +5 more
openaire   +4 more sources

Interferon-Alpha in the Treatment of Multiple Myeloma

Current Drug Targets, 2011
Interferons are soluble proteins produced naturally by cells in response to viruses. It has both anti-proliferative and immunomodulating properties and is one of the first examples of a biological response modifier use to treat the haematological malignancy multiple myeloma.
Khoo, T.L., Joshua, D., Gibson, J., Vangsted, A.J.   +3 more
openaire   +3 more sources

Interferon alpha and neuromuscular disorders

Journal of Neuroimmunology, 2009
Interferon-alpha (IFNalpha) is a potent extracellular protein mediator of host defense and homeostasis. IFNalpha has well-established direct antiviral, antiproliferative and immunomodulatory properties. The worldwide, increasing and long-term use of IFNalpha, particularly for the treatment of chronic hepatitis C virus infection, has drawn attention to ...
openaire   +3 more sources

Purification and Cloning of Interferon Alpha

2007
Interferon alpha (IFN-alpha) was approved by the US Food and Drug Administration on June 5, 1986 and paved the way for development of many other cytokines and growth factors. Nevertheless, we have barely touched the surface of understanding the multitude of human IFNs.
openaire   +3 more sources

Effects of Interferon-Alpha on Human Warts

Journal of Interferon Research, 1982
Two patients with extensive warts which were stable for two years or more were treated with human interferon-alpha to assess the ability of interferon to affect this benign tumor of viral etiology. Intramuscular administration of 96.6 and 135 million units over 12-15 weeks produced softening and decreased scaling of each patient's warts.
Ann M. Arvin, Harry L. Wechsler, Thomas C. Merigan, Monto Ho, Harry W. Haverkos, Mary C. Breinig, Kari Cantell, John A. Armstrong, George J. Pazin   +8 more
openaire   +3 more sources

Interferon-alpha in the Treatment of Essential Thrombocythemia

Leukemia & Lymphoma, 1996
Interferon alpha (IFN) inhibits the growth of megakaryocytic progenitors in normal hematopoiesis and in patients with essential thrombocythemia (ET) leading to a reduction of peripheral platelet counts. The effectiveness in the induction therapy of patients with ET is demonstrated in 11 international studies including 212 patients. With an average dose
Eva Lengfelder, Martin Griesshammer, Rüdiger Hehlmann   +2 more
openaire   +3 more sources

Maintenance with Interferon Alpha in Myeloma

1998
Although IFN maintenance treatment is routinely used in many myeloma treatment centers, its clinical efficacy is still a matter of controversy. IFN, a biologic response modifier, inhibits myeloma cell growth and stimulates important functions of the immune system.
E. Fritz, H. Ludwig
openaire   +2 more sources